A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial. (2019)
Attributed to:
MICA: BRONCH-UK a multicentre and multidisciplinary partnership grant tackling unmet needs in bronchiectasis
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1186/s13063-019-3766-9
PubMed Identifier: 31856887
Publication URI: http://europepmc.org/abstract/MED/31856887
Type: Journal Article/Review
Volume: 20
Parent Publication: Trials
Issue: 1
ISSN: 1745-6215